Human Stem-Like Cell Metabolomics for Developmental Toxicity Screening
Solution Overview
Problem
Current methods for testing developmental toxicity of pharmaceutical and chemical compounds are inadequate, relying on animal models that are inefficient and fail to accurately predict human responses due to interspecies differences, necessitating a more reliable and human-specific in vitro screening method.
Innovation Solution
The use of human stem-like cells (hSLCs) and metabolomics to assess the toxicity of compounds by analyzing metabolite profiles, which are altered in response to teratogenic agents, providing a high-throughput screening method with quantitative human endpoints.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used to test developmental toxicity, then testing can be conducted, but prediction accuracy for human responses deteriorates due to interspecies differences
Solution Approach 1:
The patent uses human stem-like cells as a simplified copy of human embryonic systems to model developmental toxicity. Instead of using complex animal models, the invention creates a human-specific in vitro system that replicates key developmental processes, thereby improving prediction accuracy for human responses while eliminating interspecies variability
Solution Approach 2:
The invention changes the fundamental parameter of test subject from animal models to human-derived cells. By using human stem-like cells that can differentiate into various tissue types, the system maintains biological relevance to human development while allowing controlled in vitro experimentation, thus resolving the contradiction between reliability and species adaptability
2Adaptability or versatility
If in vitro models are used to assess developmental toxicity, then human-specific testing is achieved, but model robustness and efficiency deteriorate due to limitations in current cell-based systems
Solution Approach 1:
The patent employs multipotent human stem-like cells that can differentiate into multiple cell lineages representing various developing tissues. This multi-functionality allows a single cell model to assess developmental toxicity across different organ systems simultaneously, enhancing both human-specific applicability and model robustness through comprehensive tissue representation
Solution Approach 2:
The invention replaces traditional in vivo mechanical/physiological systems with an in vitro metabolomics-based detection system. By using metabolite profile analysis instead of whole-organism observation, the system achieves human-specific testing while improving efficiency and robustness through quantitative, high-throughput metabolic measurements
3Productivity
If traditional toxicity testing methods are used, then screening can be performed, but throughput and efficiency deteriorate due to limitations in current screening capabilities
Solution Approach 1:
The patent replaces time-consuming in vivo animal studies and complex in vitro assays with a streamlined metabolomics-based screening system. By measuring metabolic profiles directly from cell cultures exposed to test compounds, the invention achieves high-throughput screening capability while reducing testing time through automated metabolic analysis
Solution Approach 2:
The invention changes the detection parameter from traditional endpoints (cell viability, morphological changes) to metabolic profile parameters. This parameter change enables higher throughput because metabolite levels can be quantified rapidly using mass spectrometry or NMR, significantly improving screening efficiency and reducing time loss
Data Source
AI summary
The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.